CF PharmTech Launches H-Share Full Circulation Plan; Shares Slip 2%
MT Newswires Live
Nov 26
CF PharmTech's (HKG:2652) board has approved a plan to convert 107.4 million domestic unlisted shares, representing about 26.1% of its issued share capital, into H shares, according to a Tuesday Hong Kong bourse filing.
Shares of the inhalation drug developer were down nearly 2% in Wednesday morning trade.
The company will apply to the China Securities Regulatory Commission under the H-share full-circulation scheme.
After completing required approvals and regulatory procedures, the converted shares will be listed and traded in Hong Kong.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.